# ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme

Source: https://onco.cc/trials/nct04587830/  
OnCo record `nct04587830` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Temozolomide in glioma & glioblastoma, run by Polaris Group, active and no longer recruiting.

## Summary

ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme is a phase 2 interventional study registered as NCT04587830 by Polaris Group, with 100 participants enrolled, started 2020-09-14 and due to reach its primary completion in 2027-02-28. Interventions recorded: ADI-PEG 20, Temozolomide and Placebo.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04587830
- Phase: 2
- Setting: Phase 1-2 Trial of ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme (GBM)
- Sponsor: Polaris Group
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT04587830: https://clinicaltrials.gov/study/NCT04587830

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Temozolomide](https://onco.cc/drugs/temozolomide/)
- companies: [Polaris Group](https://onco.cc/companies/polaris-group/)

---
JSON: https://onco.cc/api/v1/entities/nct04587830.json